Arya Sciences Acquisition Corp III

Nautilus Biotechnology, Inc. operates as a life sciences company. The firm develops proteomics platform for analyzing and quantifying the human proteome. The company was founded by Sujal Patel and Parag Mallick in 2016 and is headquartered in Seattle, WA.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Nautilus Biotechnology, Inc. is a life sciences company, which engages in the development of a proteomics platform for analyzing and quantifying the human proteome. Its products include Proteome Analysis System, Reagent Kits, and Software and Analysis. The company was founded by Sujal Patel and Parag Mallick in 2016 and is headquartered in Seattle, WA.

NEW YORK, June 01, 2021 (GLOBE NEWSWIRE) -- ARYA Sciences Acquisition Corp III (“ARYA”) (Nasdaq: ARYA), today announced that, due to the public health and safety concerns related to the coronavirus (COVID-19) pandemic and recommendations and orders from federal and New York authorities, ARYA is strongly encouraging that shareholders attend the extraordinary general meeting of its shareholders on June 8, 2021 at 9:00 a.m., New York City Time (the “General Meeting”) remotely by teleconference rather than in person. The purpose of the General Meeting is to vote on certain proposals relating to the previously announced Business Combination Agreement, dated as of February 7, 2021 (the “Business Combination Agreement”), by and among ARYA, Nautilus Biotechnology, Inc. (“Nautilus”) and on the transactions contemplated thereby (the “Business Combination”).

ARYA Sciences Acquisition Corp III Announces Extraordinary General Meeting Teleconference Details

SAN CARLOS, Calif. & SEATTLE--(BUSINESS WIRE)--Nautilus Biotechnology appoints Matt Murphy, former 10x Genomics and Pacific Biosciences executive, as General Counsel

Nautilus Biotechnology Appoints Matt Murphy as General Counsel

NEW YORK, Feb. 9, 2021 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Arya Sciences Acquisition Corp. III ("ARYA" or the "Company") (NASDAQ: ARYA) in connection with the Company's proposed merger...

SHAREHOLDER ALERT: WeissLaw LLP Investigates Arya Sciences Acquisition Corp. III

The stock price of ARYA Sciences Acquisition III Corp (NASDAQ: ARYA) is trading at over 60% today. This is why it happened.

ARYA Stock Price Increases Over 60%: Why It Happened

SEATTLE & NEW YORK--(BUSINESS WIRE)--Nautilus Biotechnology, Inc. ("Nautilus Biotechnology" or “Nautilus”), a company pioneering a single-molecule protein analysis platform for quantifying the human proteome, and Arya Sciences Acquisition Corp III (Nasdaq: ARYA) (“Arya III”), a special purpose acquisition company or SPAC, sponsored by Perceptive Advisors, today announced they have entered into a definitive business combination agreement. Upon closing of the transaction, Arya III will redomicile

Next-Gen Proteomics Company Nautilus Biotechnology to List on Nasdaq Through Merger with Arya Sciences Acquisition Corp III

News for Arya Sciences Acquisition Corp III Stock (ARYA)